Figure 1

Relationship between peripheral T cell cytotoxicity and clinical responses to anti-PD-1 therapy. (A) Peripheral T cell cytotoxicity according to objective tumor responses to anti–PD-1 therapy. Peripheral T cell cytotoxicity was measured prior to the initiation of anti-PD-1 therapy. Responses were evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 guidelines as a partial response (PR), stable disease (SD), or progressive disease (PD). Each dot represents one patient. The significance of differences was assessed using the Mann–Whitney U test. (B) Receiver operating characteristic (ROC) curves for peripheral T cell cytotoxicity to differentiate patients with PR and SD from those with PD. (C) Kaplan–Meier curves for the progression-free survival (PFS) of patients for the first-line or later treatments according to peripheral T cell cytotoxicity levels. (D) Kaplan–Meier curves for the PFS of patients for the second-line or later treatments according to peripheral T cell cytotoxicity levels. (E) Kaplan–Meier curves for the overall survival (OS) of patients for the first-line or later treatments according to peripheral T cell cytotoxicity levels. (F) Kaplan–Meier curves for the OS of patients for the second-line or later treatments according to peripheral T cell cytotoxicity levels. The significance of differences was assessed using the log-rank test (C–F). AUC, area under the curve.